Deucravacitinib in Psoriasis: Three-Year Safety and Efficacy Results

Another important data update presented at EADV 2023 was presented by distinguished Professor April Armstrong, Chief of Dermatology at UCLA. She unveiled groundbreaking three-year data on the safety and efficacy of deucravacitinib—a first-in-class TYK2 inhibitor. The insights not only affirm deucravacitinib’s equivalence to biological treatments in terms of efficacy, but also highlight its safety profile with no escalation in adverse events.